Accounts Payable
The latest quarterly a/p is $149.80 Million with a quarter-over-quarter change of +99.73%. Accounts Payable (A/P) represents money the company owes to suppliers and vendors for goods and services received but not yet paid for.
PODD A/P
Reported quarterly accounts payable; no daily interpolation.
Current A/P
$149.80M
$149.80 Million
Quarter-over-Quarter Change
+99.73%
vs. $75.00M prior quarter
Historical Data
80
Quarters of data available
Quarterly A/P History
| Period | A/P | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $149.80M | +$74.80M | +99.73% |
| Q4 2025 | $75.00M | +$26.80M | +55.60% |
| Q3 2025 | $48.20M | $-47.90M | -49.84% |
| Q2 2025 | $96.10M | +$38.50M | +66.84% |
| Q1 2025 | $57.60M | +$37.80M | +190.91% |
| Q4 2024 | $19.80M | $-20.50M | -50.87% |
| Q3 2024 | $40.30M | $-36.50M | -47.53% |
| Q2 2024 | $76.80M | +$900,000 | +1.19% |
| Q1 2024 | $75.90M | +$56.70M | +295.31% |
| Q4 2023 | $19.20M | $-58.60M | -75.32% |
| Q3 2023 | $77.80M | $-29.70M | -27.63% |
| Q2 2023 | $107.50M | +$21.60M | +25.15% |
| Q1 2023 | $85.90M | +$55.10M | +178.90% |
| Q4 2022 | $30.80M | $-31.30M | -50.40% |
| Q3 2022 | $62.10M | +$4.90M | +8.57% |
| Q2 2022 | $57.20M | +$5.00M | +9.58% |
| Q1 2022 | $52.20M | +$14.50M | +38.46% |
| Q4 2021 | $37.70M | $-20.30M | -35.00% |
| Q3 2021 | $58.00M | +$8.70M | +17.65% |
| Q2 2021 | $49.30M | $-9.80M | -16.58% |
| Q1 2021 | $59.10M | +$5.00M | +9.24% |
| Q4 2020 | $54.10M | $-2.90M | -5.09% |
| Q3 2020 | $57.00M | +$21.40M | +60.11% |
| Q2 2020 | $35.60M | $-800,000 | -2.20% |
| Q1 2020 | $36.40M | $-18.10M | -33.21% |
| Q4 2019 | $54.50M | +$33.26M | +156.53% |
| Q3 2019 | $21.25M | $-3.51M | -14.17% |
| Q2 2019 | $24.75M | $-2.08M | -7.76% |
| Q1 2019 | $26.83M | +$1.33M | +5.23% |
| Q4 2018 | $25.50M | $-1.34M | -5.01% |
| Q3 2018 | $26.84M | +$1.65M | +6.57% |
| Q2 2018 | $25.19M | $-8.65M | -25.57% |
| Q1 2018 | $33.85M | +$9.43M | +38.64% |
| Q4 2017 | $24.41M | $-4.24M | -14.78% |
| Q3 2017 | $28.65M | +$16.41M | +133.99% |
| Q2 2017 | $12.24M | +$5.83M | +90.91% |
| Q1 2017 | $6.41M | $-6.75M | -51.27% |
| Q4 2016 | $13.16M | $-5.05M | -27.74% |
| Q3 2016 | $18.21M | $-3.39M | -15.70% |
| Q2 2016 | $21.61M | +$8.12M | +60.25% |
| Q1 2016 | $13.48M | $-1.73M | -11.38% |
| Q4 2015 | $15.21M | $-401,000 | -2.57% |
| Q3 2015 | $15.61M | $-2.30M | -12.85% |
| Q2 2015 | $17.92M | +$3.67M | +25.76% |
| Q1 2015 | $14.25M | $-413,000 | -2.82% |
| Q4 2014 | $14.66M | $-3.07M | -17.30% |
| Q3 2014 | $17.73M | $-884,000 | -4.75% |
| Q2 2014 | $18.61M | $-2.37M | -11.31% |
| Q1 2014 | $20.98M | +$1.62M | +8.39% |
| Q4 2013 | $19.36M | +$4.24M | +28.06% |
| Q3 2013 | $15.12M | +$3.68M | +32.13% |
| Q2 2013 | $11.44M | +$2.90M | +33.91% |
| Q1 2013 | $8.54M | $-817,000 | -8.73% |
| Q4 2012 | $9.36M | $-6.86M | -42.27% |
| Q3 2012 | $16.22M | +$2.53M | +18.48% |
| Q2 2012 | $13.69M | $-2.42M | -15.02% |
| Q1 2012 | $16.11M | +$4.69M | +41.07% |
| Q4 2011 | $11.42M | +$2.81M | +32.71% |
| Q3 2011 | $8.60M | $-765,000 | -8.17% |
| Q2 2011 | $9.37M | +$3.16M | +50.80% |
| Q1 2011 | $6.21M | +$1.32M | +26.93% |
| Q4 2010 | $4.89M | $-259,000 | -5.03% |
| Q3 2010 | $5.15M | $-3.97M | -43.54% |
| Q2 2010 | $9.13M | +$5.85M | +178.55% |
| Q1 2010 | $3.28M | $-2.59M | -44.17% |
| Q4 2009 | $5.87M | +$687,000 | +13.25% |
| Q3 2009 | $5.18M | $-397,000 | -7.11% |
| Q2 2009 | $5.58M | $-399,000 | -6.67% |
| Q1 2009 | $5.98M | $-1.31M | -17.99% |
| Q4 2008 | $7.29M | +$1.33M | +22.23% |
| Q3 2008 | $5.96M | $-19,000 | -0.32% |
| Q2 2008 | $5.98M | $-1.42M | -19.12% |
| Q1 2008 | $7.40M | +$2.85M | +62.83% |
| Q4 2007 | $4.54M | +$392,000 | +9.44% |
| Q3 2007 | $4.15M | $-1.33M | -24.30% |
| Q2 2007 | $5.49M | +$798,000 | +17.03% |
| Q1 2007 | $4.69M | +$1.24M | +35.86% |
| Q4 2006 | $3.45M | $-125,000 | -3.50% |
| Q3 2006 | $3.58M | +$1.95M | +120.14% |
| Q4 2005 | $1.62M | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy